Age Pattern Related Moribity and Mortality among COVID-19 Patients: Indian Chapter

Main Article Content

Adiesh Sood


The COVID-19 till date has groped in around million lives across the globe that includes children and elderly who became a victim of this pandemic. During course of this pandemic, there has been discussion of age related vulnerability to the disease and the preventive measures and policies implemented by various countries across the globe. The elderly have suffered a disproportionate burden of COVID-19. Patients associated co-morbidities pose a greater threat to that group as compared to general population. The epidemiological data and Case Fatality Ratio (CFR) collected from countries vary significantly but give a vivid picture of the situation of the pandemic in each region. Hence, the author reviewed the published data from several countries to investigate relationship between age and COVID-19 mortality and morbidity. The author also took the time to study briefly about the role of angiotensin converting enzyme 2 (ACE2) as a receptor against the new coronavirus SARS-CoV-2. The author also reviewed the literature for studies explaining the difference in the physiological inflammatory response to SARS-CoV-2 infection according to age.

Thus, the information achieved from these data will prove to be useful in determining the precautionary and preventive policies irrational treatment of COVID-19.

COVID-19, SARS-CoV-2, age, CFR, mortality, morbidity, ACE2, pandemic.

Article Details

How to Cite
Sood, A. (2020). Age Pattern Related Moribity and Mortality among COVID-19 Patients: Indian Chapter. International Journal of TROPICAL DISEASE & Health, 41(16), 45-57.
Review Article


Timeline of WHO’s response to COVID-19, 30 July, WHO; 2020. Accessed 28 July, 2020 Available:

Reported COVID-19 cases and deaths by Country, Territory, or Conveyance. Accessed 17 August, 2020 Available:

Cesari M, Proietti M. COVID-19 in Italy: ageism and decision making in a pandemic. J Am Med Dir Assoc. 2020;21:576–577.

Case Fatality Ratio vs Total confirmed COVID-19 deaths. Accessed 17 August, 2020 Available:

Surveillances V. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. 2020; 2(8):113-122.

Kim DH, Choe YJ, Jeong JY. Understanding and interpretation of case fatality rate of coronavirus disease 2019. J Korean Med Sci. 2020;35:e137.

Pyrc K, Berkhout B, Van Der Hoek L. Identification of new human coronaviruses. Expert review of anti-infective therapy. 2007;5(2):245-253.

Population in different age groups and their proportions to total population. Office of the Registrar General & Census Commissioner, India, Ministry of Home Affairs, Government of India. Accessed 16 August, 2020 Available:

Sushmi Dey. 43% of Covid-19 deaths in India in 30-59 yrs age band. The Times Of India; 2020. Accessed 21 July, 2020 Available:

IIPS; Covid and mortality: India’s perspective Accessed 16 August, 2020 Available:

NYC Department of Health and Mental Hygiene. Coronavirus-data. Accessed 18 July 2020 Available:

Provisional counts of number of deaths registered in England and Wales, including deaths involving COVID-19 pandemic by age, sex and region. Accessed 25 August, 2020 Available:

Older adults and COVID-19. Guidelines laid by the CDC Accessed 18 August, 2020 Available:

Koo BK, Bang JH, Kim SY, Kim EJ, Park SW. Glove-Wall System for Respiratory Specimen Collection and COVID-19 Mass Screening. Infect Chemother. 2020;52:219–221.

Leung C. Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China. Mech Ageing Dev. 2020;188:111255.

Soutik Biswas. “Five key questions about India's rising Covid-19 infections” 2020 BBC NEWS. Accessed 2 August, 2020 Available:

Chatterjee K, Chatterjee K, Kumar A, Shankar S. Healthcare impact of COVID-19 epidemic in India: A stochastic mathematical model. Medical Journal Armed Forces India; 2020.

Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, Bao L, Deng W, Gao H, Xiang Z, Xiao C, Lv Q, Gong S, Liu J, Song Z, Qu Y, Xue J, Wei Q, Liu M, Wang G, Wang S, Yu H, Liu X, Huang B, Wang W, Zhao L, Wang H, Ye F, Zhou W, Zhen W, Han J, Wu G, Jin Q, Wang J, Tan W, Qin C. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020;3:93–97.

Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31:578–585.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–374.

Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev; 2020.

“Updates on COVID-19.” Pib.Gov.In. Accessed 2 August, 2020 Available:

“Biopharma products n development for COVID-19 Accessed 7 August, 2020 Available at:


Dandona L, Dandona R, Kumar GA, Shukla DK, Paul VK, Balakrishnan K, Nandakumar A. Nations within a nation: variations in epidemiological transition across the states of India, 1990–2016 in the Global Burden of Disease Study. The Lancet. 2017;390(10111):2437-2460.

Indian Council of Medical Research, Public Health Foundation of India and Institute for Health Metrics and Evaluation, “India: Health of the Nation’s States – The India State-Level Disease Burden Initiative,” Indian Council of Medical Research, Public Health Foundation of India and Institute for Health Metrics and Evaluation; 2017. Accessed 28 July, 2020 Available: Initiative_-_Full_Report%5B1%5D.pd

Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80:e14–8.

Kim T. Improving preparedness for and response to coronavirus disease 19 (COVID-19) in long-term care hospitals in Korea. Infect Chemother. 2020;52:133–141.

Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV2infection in returning travelers from Wuhan, China. N Engl J Med. 202;382:1278–80.

Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020. Epub; 2020.

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong, S. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics; 2020.

Olson DR, Simonsen L, Edelson PJ, Morse SS. Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City. Proc Natl Acad Sci USA. 2005;102:11059–11063.

Kliegman RM, St Geme JW, Blum NJ, Shah SS, Takser RC, Wilson KM. Edition 20. Elsevier; Philadelphia, PA: Nelson textbook of pediatrics; 2020.

Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Carducci FIC, Krivec U. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health; 2020.

Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics. J Formos Med Assoc. 2020;119:670–673

Tosato F, Bucciol G, Pantano G, Putti MC, Sanzari MC, Basso G, Plebani M. Lymphocytes subsets reference values in childhood. Cytometry A. 2015;87:81–85.

Kuiken T Fouchier RAM Schutten M Rimmelzwaan GF Van Amerongen G Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263–270.

Huang C Wang Y Li X Ren L Zhao J Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506

Dong Y Mo X Hu Y Qi X Jiang F Epidemiology of COVID-19 among children In China. Pediatrics. 2020;10:0702–0702.

Cristiani L, Mancino E, Matera L, Nenna R, Pierangeli A, Scagnolari C, Midulla F. Will children reveal their secret? The coronavirus dilemma. Eur Respir J. 2020;55:2000749.

Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355–368.

Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53:371–372.

Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T, Gao W, Cheng C, Tang X, Wu X, Wu Y, Sun B, Huang S, Sun Y, Zhang J, Ma T, Lessler J, Feng T. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis; 2020

Guo, J. et al. Effects of angiotensin II type 1 receptor antagonist on rats with septic shock. Int. J. Clin. Exp. Med. 2015;8:7867–7871.

Sodhi CP, et al. A dynamic variation of pulmonary ACE2 is required to modulate neutrophilic inflammation in response to Pseudomonas aeruginosa lung infection in mice. J. Immunol. 2019;203:3000–3012.

Watkins J. Preventing a covid-19 pandemic. BMJ. 2020;368:m810.

Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653-1659.

Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78:2166–2171.

Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016;6:19840.

Schouten LR. et al. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Ann. Intensive Care. 2019; 9:55.

Olin A. et al. Stereotypic immune system development in newborn children. Cell. 2018;174:1277–1292.e14.

“COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers”, WHO; 2020. Accessed 25 July, 2020 Available:

Wong HR, Freishtat RJ, Monaco M, Odoms K, Shanley TP. Leukocyte subset-derived genome-wide expression profiles in pediatric septic shock. Pediatr. Crit. Care Med. 2010;11:349–355.